azidothymidine homodinucleotide

erythrocytes loaded with AZT(p2)AZT act as bioreactors ensuring sustained release of the antiretroviral drug azidothymidine

Also Known As:

AZT(p2)AZT; AZTp2AZT; di(thymidine-3'-azido-2',3'-dideoxyriboside)-5'-5'-P1-P2-pyrophosphate; di-(thymidine-3'-azido-2',3'-dideoxy-D-riboside)-5'-5'-p1-p2-pyrophosphate

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Murine Acquired Immunodeficiency Syndrome (MAIDS) 03/01/1998 - "Inhibition of murine AIDS by a new azidothymidine homodinucleotide." 06/01/1999 - "The treatments including AZT and erythrocytes loaded with GSH alone or with GSH plus AZTp2AZT provided similar results and were most effective in inhibiting the progression of MAIDS; they reduced splenomegaly, lymphadenopathy, and hypergammaglobulinemia by about 70%, 90% and 83%, respectively, when compared with infected animals at 10 weeks postinfection. " 03/01/1998 - "A new antiretroviral drug (azidothymidine homodinucleotide, AZTp2AZT), designed for the protection of macrophages against retroviral infection, was evaluated in a murine retrovirus-induced immunodeficiency model of AIDS (MAIDS) alone and in combination with oral azidothymidine (AZT). "
2.	Splenomegaly 03/01/1998 - "AZTp2AZT treatment was found to reduce lymphoadenopathy (48%), splenomegaly (26%), and BM5d proviral DNA content in lymph nodes, spleen, and brain of 37%, 40%, and 36%, respectively, compared with untreated animals. " 03/01/1998 - "AZT administration in drinking water (0.25 mg/ml) was more effective than administration of AZTp2AZT encapsulated into erythrocytes in reducing lymphoadenopathy, splenomegaly, gammaglobulinemia, and proviral DNA content in lymph nodes, but it caused a reduction in erythrocyte count and hematocrit levels. " 06/01/1999 - "The treatments including AZT and erythrocytes loaded with GSH alone or with GSH plus AZTp2AZT provided similar results and were most effective in inhibiting the progression of MAIDS; they reduced splenomegaly, lymphadenopathy, and hypergammaglobulinemia by about 70%, 90% and 83%, respectively, when compared with infected animals at 10 weeks postinfection. "
3.	Hypergammaglobulinemia (Hyperimmunoglobulinemia) 06/01/1999 - "The treatments including AZT and erythrocytes loaded with GSH alone or with GSH plus AZTp2AZT provided similar results and were most effective in inhibiting the progression of MAIDS; they reduced splenomegaly, lymphadenopathy, and hypergammaglobulinemia by about 70%, 90% and 83%, respectively, when compared with infected animals at 10 weeks postinfection. "
4.	Lymphadenopathy 06/01/1999 - "The treatments including AZT and erythrocytes loaded with GSH alone or with GSH plus AZTp2AZT provided similar results and were most effective in inhibiting the progression of MAIDS; they reduced splenomegaly, lymphadenopathy, and hypergammaglobulinemia by about 70%, 90% and 83%, respectively, when compared with infected animals at 10 weeks postinfection. "
5.	Infections 04/30/1996 - "Synthesis and targeted delivery of an azidothymidine homodinucleotide conferring protection to macrophages against retroviral infection." 03/01/1998 - "A new antiretroviral drug (azidothymidine homodinucleotide, AZTp2AZT), designed for the protection of macrophages against retroviral infection, was evaluated in a murine retrovirus-induced immunodeficiency model of AIDS (MAIDS) alone and in combination with oral azidothymidine (AZT). "

Related Drugs and Biologics

1.	Dihydrotachysterol (AT 10)
2.	azidothymidine homodinucleotide
3.	Drinking Water
4.	Zidovudine (Retrovir)
5.	DNA (Deoxyribonucleic Acid)